Alaunos Therapeutics Inc. logo

TCRT

Alaunos Therapeutics Inc.

$1.16

Earnings Summary

Revenue
$0Mn
Net Profits
$-7.84Mn
Net Profit Margins
-784300%

Highlights

Revenue:

Alaunos Therapeutics Inc.’s revenue jumped +Inf% since last year same period to $0Mn in the Q1 2024. On a quarterly growth basis, Alaunos Therapeutics Inc. has generated 0% jump in its revenue since last 3-months.

Net Profits:

Alaunos Therapeutics Inc.’s net profit jumped 16.14% since last year same period to $-7.84Mn in the Q1 2024. On a quarterly growth basis, Alaunos Therapeutics Inc. has generated 0% jump in its net profits since last 3-months.

Net Profit Margins:

Alaunos Therapeutics Inc.’s net profit margin jumped NaN% since last year same period to -784300% in the Q1 2024. On a quarterly growth basis, Alaunos Therapeutics Inc. has generated 0% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Alaunos Therapeutics Inc. post its latest quarter earnings

EPS Estimate Current Quarter
-0.45
EPS Estimate Current Year
-0.45

Highlights

EPS Estimate Current Quarter:

Alaunos Therapeutics Inc.’s earning per share (EPS) estimates for the current quarter stand at -0.45 - a 0% jump from last quarter’s estimates.

EPS Estimate Current Year:

Alaunos Therapeutics Inc.’s earning per share (EPS) estimates for the current year stand at -0.45.

Key Ratios

Key ratios of the Alaunos Therapeutics Inc. post its Q1 2024 earnings

Earning Per Share (EPS)
-0.49
Return on Assets (ROA)
-0.49
Return on Equity (ROE)
-1.57

Highlights

Earning Per Share (EPS):

Alaunos Therapeutics Inc.’s earning per share (EPS) fell -1125% since last year same period to -0.49 in the Q1 2024. This indicates that the Alaunos Therapeutics Inc. has generated -1125% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Alaunos Therapeutics Inc.’s return on assets (ROA) stands at -0.49.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Alaunos Therapeutics Inc.’s return on equity (ROE) stands at -1.57.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2024-04-01
-0.45
-0.49
-8.89%